• Tuhura Biosciences outlined a $50 million non-equity credit facility and royalty transaction, projecting cash runway through Q1 2028.
• Facility terms include 5 years of interest-only payments at 12% on drawn amounts, a 10% commitment fee payable in shares at $2.66 subject to shareholder approval, a 1.5% annual cash fee.
• Royalty applies only to IFx-2.0 sales, described as low- to mid-single digits up to $450 million in annual sales.
• Lead program IFx-2.0 remains in a Phase 3 accelerated-approval study in first-line advanced/metastatic Merkel cell carcinoma, with topline data expected in 2H 2027 under an FDA SPA.
• Pipeline updates include a VISTA-inhibiting antibody program in AML with a Phase 1b/2 start targeted for 2H 2026, alongside immune-modulating ADC proof-of-concept work with data targeted for 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief on May 19, 2026, and is solely responsible for the information contained therein.